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tions for both patients and providers, yet has received little atten-
tion since Part D went into effect. Our objective was to deter-
mine the impact of Medicare Part D on MA enrollment.
METHODS: State-level data from the Centers for Medicare 
and Medicaid Services (CMS) were used to calculate overall
Medicare enrollment (including dual eligibles), enrollment in
managed care plans, and enrollment in MA plans with drug cov-
erage (MA-PDs) and stand-alone prescription drug plans (PDPs)
from January 2003–June 2006. States were classiﬁed as having
low, medium, or high penetration based on tertile of penetration
for the ﬁrst quarter of 2003 (1Q03). The effect of Part D on
managed care enrollment penetration in states with low,
medium, and high penetration was assessed using linear regres-
sion. RESULTS: Nationwide, MA penetration increased from
14.0% in 4Q05 to 15.3% in 2Q06. MA penetration signiﬁcantly
increased following the implementation of Part D, but only in
states which had low Medicare managed care penetration prior
to Part D (p < 0.05). CONCLUSION: New MA enrollees living
in areas that historically had little experience with managed care
may face interruptions in health care or difﬁculties accessing
care, at least initially. CMS should carefully monitor the health
care patterns of new MA enrollees to ensure that beneﬁciary
health is not compromised.
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OBJECTIVES: Medication nonadherence is an important
problem in older populations, and is affected by numerous
factors. The aim of this study was to examine the relationship
between gender and medication adherence in older adults 
with chronic diseases. METHODS: A longitudinal cohort 
study was conducted in older adults (aged >65 years) who com-
pleted a health status assessment and were enrolled in a health
maintenance organization. The study sample included patient
cohorts with four major chronic diseases. Medication Possession
Ratio (MPR) was used as a measure of medication adherence 
in Type 2 Diabetes Mellitus (n = 775 patients), asthma (n =
129 patients), and overactive bladder (OAB) (n = 275 patients).
Persistence rate was used as the measure of medication 
adherence in glaucoma (n = 268 patients). RESULTS: For glau-
coma patients, males had a signiﬁcant 0.111-point (22.2%
increase over mean) decrease in medication persistence (p <
0.05). In male asthma patients, there was a similar 0.13-point
(38% increase over mean) decrease in medication adherence as
measured by the Med-Total score (p < 0.05). A 0.0051-point
increase (0.8% increase over mean) in MPR was found in male
patients receiving continuous antidiabetic pharmacotherapy (p >
0.05). In male OAB patients, there was a 0.025-point increase
(6% increase over mean) in MPR for antimuscarinic medications
(p > 0.05). CONCLUSION: This study found signiﬁcant but
unexplained associations between male gender and decreased
medication adherence in glaucoma and asthma patients. No sig-
niﬁcant adherence differences were found between males and
females for Type 2 diabetic and OAB patients. This suggests 
that gender can be a predictor of medication adherence but this
effect varies depending on which chronic disease the patient
suffers from. Further study of these gender differences is war-
ranted in order to improve medication adherence and aid in
disease intervention.
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OBJECTIVES: Although several studies have described the
burden of Premenstrual Dysphoric Disorder (PMDD) impacts
women’s lives, few undertook a quantitative approach. This
study is an attempt to quantify the burden of PMDD on health-
related quality of life (HRQoL) in comparison to speciﬁc chronic
conditions in the US general population. METHODS: The
burden of PMDD on HRQoL was estimated by comparing SF-
12 scores between women identiﬁed as being “at risk for
PMDD” with SF-12 scores observed in the general US popula-
tion. Additional comparisons were made to several chronic
health conditions. SF-12 normative values of the general popu-
lation were estimated through regression adjusted to match the
age and disease comorbidity of the PMDD patient group. Sig-
niﬁcance tests between the means across samples were compared.
Medical expenditures were estimated and compared for women
who were “at risk for PMDD” and women with no reported
chronic conditions. RESULTS: All SF-12 measures of PMDD
were signiﬁcantly below the adjusted US general population
norms. The burden of PMDD was greater on mental/emotional
than on physical HRQoL. The burden of PMDD on HRQoL was
greater than that of chronic back pain; similar to type 2 diabetes,
hypertension, osteoarthritis and rheumatoid arthritis; and largely
comparable to depression. Age, PCS, and MCS scores were used
to predict monthly medical expenditures using data from the
annual Medical Expenditures Panel Survey (2001). The mean
predicted monthly medical expenditure for women “at risk for
PMDD” was $222.3 (SD = $107.3) and $134.0 (SD = $43.4) for
women with no reported chronic conditions (p < 0.0001). CON-
CLUSION: PMDD is associated with substantial burden on
physical and mental aspects of HRQoL, and may be related to
increased medical expenditures.
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OBJECTIVES: Many of the large ongoing national surveys of
the US population contain a question that asks for the respon-
dent’s self-reported health status: “excellent,” “very good,”
“good,” “fair” or “poor.” These surveys could be used to con-
duct cost-utility analyses of health care policies, treatments 
or other interventions if quality-of-life (QOL) weights for the
self-reported health statuses were also available. The objective of
this study was to produce nationally representative QOL weights
for self-reported health status and for 10 priority health condi-
tions, by a series of demographic variables. METHODS: The
Medical Expenditure Panel Survey contains the questions from
the EQ-5D health status measure. A recent study has calculated
time-trade-off-derived QOL weights corresponding to the EQ-
5D health states for a large US sample. We use these data to con-
struct QOL weights for the ﬁve self-reported health status
categories and 10 priority health conditions, by a series of demo-
graphic variables. RESULTS: Mean and median QOL weights
were produced for self-reported health status, the 10 priority
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health conditions, and the demographic variables. We also report
QOL weights for the self-reported health state and priority
health conditions, by the demographic variables. Finally, ordi-
nary least squares and CLAD regression equations were used to
estimate adjusted QOL weights for these variables. CONCLU-
SION: By providing nationally representative QOL weights for
self-reported health status and priority health conditions, by
demographic variable, we have facilitated the use of large
national surveys for conducting cost-utility analysis and
increased their value to researchers and policy makers.
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OBJECTIVES: To identify treatment satisfaction thresholds for
interpreting treatment–related changes in vasomotor symptoms,
and determine the doses of desvenlafaxine succinate (DVS) that
effectively provide relief of vasomotor symptoms considered
important by menopausal women. METHODS: Efﬁcacy and
treatment satisfaction were assessed in 620 postmenopausal
women with ≥7 moderate-to-severe vasomotor symptoms/day
participating in a double-blind, placebo-controlled trial ran-
domized to placebo or DVS 50, 100, 150, or 200 mg. Number
and severity of hot ﬂushes and number of nighttime awakenings
were recorded in daily diaries for 12 weeks of treatment.
Responses to the Menopausal Symptoms Treatment Satisfaction
Questionnaire at week 12 were compared with efﬁcacy results.
The treatment satisfaction threshold was anchored by the dif-
ference in the average symptom change among women report-
ing “neutral” satisfaction compared with women reporting
“satisﬁed,” without deference to treatment group. RESULTS:
Greater percentages of participants in the DVS groups reported
being “satisﬁed” or “extremely satisﬁed” with daytime and
nighttime control of hot ﬂushes compared with placebo
(57–75% versus 52%; P = 0.009 and 63–80% versus 54%; P =
0.003). These efﬁcacy results were greatest in the 100 mg DVS
group. The treatment satisfaction threshold was 1.64 for daytime
hot ﬂushes, 0.20 for the hot ﬂushes severity score, and 0.42 for
nighttime awakenings. Statistically signiﬁcant efﬁcacy outcomes
with DVS 100 mg compared with placebo exceeded all treatment
satisfaction thresholds. CONCLUSION: Among menopausal
women in this study, the treatment satisfaction thresholds in
vasomotor symptoms reduction over placebo were 1.64 hot
ﬂushes per day and about one nighttime awakening every other
night. Exceeding these vasomotor symptoms change thresholds
indicated that the 100 mg dose of DVS had achieved important
and meaningful improvements from the participants’ perspec-
tive. DVS is an effective option for treatment of vasomotor symp-
toms associated with menopause.
INFECTION—Clinical Outcomes Studies
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OBJECTIVES: To determine the cost-effectiveness of treatments
for patients with acute (RSA) and chronic rhinosinusitis (RSC)
that are available at the Mexican Institute of Social Security
(IMSS). METHODS: Cost-effectiveness analysis of RSA and
RSC treatment from an institutional perspective. Effectiveness
outcome was deﬁned as the percentage of cure and this infor-
mation was taken from the literature. Use of resources was
obtained from an expert panel and unit costs were taken from
Administrative and Financial departments from IMSS. Estimated
costs are expressed in US dollars (USD). A decision tree with a
Bayesian approach included the following therapeutic alterna-
tives: ciproﬂoxacin, gatiﬂoxacin, trimetoprim/sulfametoxazol
(TMP/SMX), amoxicilin/clavulanic acid (AAC) and clindamicin.
The decision tree was designed by IMSS experts according to
clinical guidelines. Univariate and bivariate sensitivity analyses
were carried out. RESULTS: Treatment for RSA with AAC
showed a mean cost per cured patient of $79.8 USD. The remain-
ing antibiotics had a higher cost per unit of success, and there-
fore the results showed that AAC was the best alternative
considering this criterion. The rapy that showed a larger per-
centage of cured patients in RSC was clindamicin (cost per unit
of success 666.3 USD); however, the therapeutic alternative with
the lowest cost per successful unit was the one based on
ciproﬂoxacin, which dominates gatiﬂoxacin and AAC. CON-
CLUSION: Ciproﬂoxacin is a cost-effective alternative for both,
RSA and RSC; however, AAC is also a good alternative in RSA
when resources are constrained. Sensitivity analysis showed the
strength of the base study results.
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OBJECTIVES: Assess differences in treatment response between
weight-based peginterferon alfa-2b (PEG2b) or standard dosed
peginterferon alfa-2a (PEG2a) plus weight-based ribavirin
(RBV); identify patient variables that may predict treatment
response; and evaluate differences in cost-effectiveness.
METHODS: We compared two retrospective assessments of the
treatment of hepatitis C virus (HCV) infected patients at two 
different VAs. The primary outcome was sustained virologic
response (SVR), deﬁned as an undetectable viral load 6 months
post-therapy completion. All patients were treatment naïve and
had received at least 2 doses of PEG 2a or 2b plus RBV prior to
January 2005 (n = 151). RESULTS: SVR among genotype 1 and
genotype 2/3 patients was 21% and 71% for PEG2a versus 20%
and 70% for PEG2b, respectively. Premature treatment discon-
tinuation due to an adverse event occurred among 36% of
PEG2a and 40% of PEG2b patients. The overall relapse rate was
29% for each regimen. There was a statistically signiﬁcant dif-
ference in baseline age and weight between the two groups.
Overall mean age +SD was 52 + 6 years for PEG2a and 49 + 7
years for PEG2b (P = 0.001); overall mean body weight was 94
+ 18 kg for PEG2a and 86 + 13 for PEG2b (P = 0.008). Cost per
successful outcome (deﬁned as SVR) for genotype 1 and geno-
type 2/3 was $36,567 and $4958 for PEG2a versus $38,670 and
$5060 for PEG2b, respectively. CONCLUSION: There were no
statistically signiﬁcant differences between peginterferon alfa-2a
and peginterferon alfa-2b in terms of treatment response or cost-
effectiveness; however dissimilarities in the variables associated
